Sichuan Jinshi Technology Co Ltd Class A

002951.CS

Jinshi Yayao's 2026 interim net profit reaches 95.4742 million yuan

Jinshi Yayao released its 2026 interim report, with total operating revenue of 491 million yuan, down 0.22% year-on-year, and net profit attributable to the parent company of 95.4742 million yuan. Net cash inflow from operating activities was 107 million yuan, down 27.26% year-on-year. The company's asset-liability ratio was 15.80%, gross margin was 60.52%, ROE was 3.65%, and diluted earnings per share was 0.24 yuan. Total asset turnover was 0.15 times, and inventory turnover was 0.93 times. The number of shareholders was 29,100, and the top ten shareholders held 52.52% of the total share capital.

002951.CS

Jiemian·24dRead more →

002951.CS▼

Jinshi Technology reports net loss of 4.97 million yuan in 2026 interim report

Jinshi Technology released its 2026 interim report, with net profit attributable to the parent company at negative 4.97 million yuan. The company's total operating revenue was 86.9986 million yuan, down 64.13% year-on-year, a decrease of 156 million yuan. Net cash flow from operating activities was negative 60.8521 million yuan. The latest asset-liability ratio was 23.03%, gross margin was 21.87%, and ROE was negative 0.33%.

002951.CS ▼

Jiemian·26dRead more →

002951.CS▲

Jinshi Asia Pharmaceutical Subsidiary Dier Pharmaceutical's Diclofenac Sodium Sustained-Release Tablets Proposed for Centralized Procurement

Jinshi Asia Pharmaceutical's wholly-owned second-tier subsidiary, Zhejiang Dier Pharmaceutical Co., Ltd., has had its diclofenac sodium sustained-release tablets proposed for selection in the 12th round of national centralized drug procurement. The proposed selected product generated sales revenue of 6.2231 million yuan in 2025 for the same specification, accounting for 0.60% of the company's 2025 operating revenue. Total 2025 sales revenue for the full diclofenac sodium sustained-release tablet category was 38.1834 million yuan, representing 3.68% of the company's 2025 operating revenue. In the first quarter of 2026, Jinshi Asia Pharmaceutical achieved revenue of 331 million yuan and net profit attributable to the parent company of 116 million yuan.

002951.CS ▲

财中社·47dRead more →

002951.CS▼

Jinshi Yayao Waives Pre-emptive Rights in Lingye Pharma Capital Increase, Stake Passively Diluted to 30.12%

Jinshi Yayao announced that the company has waived its pre-emptive subscription rights in the current capital increase of its associate, Hangzhou Lingye Pharmaceutical Technology Co., Ltd. Lingye Pharma plans to introduce a new strategic investor, Lishui Green Industry Development Fund Co., Ltd., with a capital increase of 40 million yuan and an addition of 1.01 million yuan in registered capital. Before the capital increase, Jinshi Yayao held a 32.43% stake in Lingye Pharma. After the capital increase, its shareholding will be passively diluted to 30.12%. The company's waiver of pre-emptive subscription rights in this capital increase constitutes a related-party transaction.

002951.CS ▼

财中社·64dRead more →

002951.CS▼

Jinshi Technology: Supercapacitor Business Has No Orders on Hand for Now

Jinshi Technology, which hit the daily limit up for two consecutive days, issued a stock trading abnormality announcement stating that its supercapacitor business is still in the early development stage, with a relatively low proportion of overall revenue, and currently has no orders on hand. There is still uncertainty as to whether this business can bring good performance returns to the company in the future. The company also stated that it is not involved in liquid cooling related business or optical communication business at present.

002951.CS ▼

证券时报·73dRead more →